#151271

Anti-BarX2 [BAR X2 8A7/1]

Cat. #151271

Anti-BarX2 [BAR X2 8A7/1]

Cat. #: 151271

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-4 weeks

Target: BarX2

Class: Monoclonal

Application: ELISA ; IHC ; IF ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Institute: Cancer Research Technology

Tool Details
Target Details
Applications
Handling

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-BarX2 [BAR X2 8A7/1]
  • Research fields: Cancer;Cell biology;Genetics
  • Clone: BAR X2 8A7/1
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: ELISA ; IHC ; IF ; WB
  • Description: BarX2 is a tumour suppressor gene that encodes for a transcription factor known to regulate the expression of cell adhesion molecules in the mouse.
  • Immunogen: MBP-tagged BarX2
  • Isotype: IgG1
  • Myeloma used: Sp2/0-Ag14

Target Details

  • Target: BarX2
  • Target background: BarX2 is a tumour suppressor gene that encodes for a transcription factor known to regulate the expression of cell adhesion molecules in the mouse.

Applications

  • Application: ELISA ; IHC ; IF ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Dry ice

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.